---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-075030"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2022-11-25T23:59:59+00:00"
generated_at: "2026-06-21T13:05:22.941150+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences receives Nasdaq delisting notice; trading to be suspended Dec 2, 2022

## Summary
- Received second Nasdaq deficiency letter on Nov 23, 2022 for failing $2.5M stockholders' equity requirement.
- As of Sept 30, 2022, stockholders' equity was $2,227,768, below the minimum.
- Trading suspension scheduled for Dec 2, 2022 unless appeal is filed.
- Company intends to request hearing before an independent panel to stay suspension.
- No immediate effect on trading of units, common stock or warrants under REVBU, REVB, REVBW.

## SEC filing metadata
- accession: 0001213900-22-075030
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2022-11-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/0001213900-22-075030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/ea169284-8k_revelation.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-075030
- JSON: https://secwatch.observer/filing/0001213900-22-075030.json
- Plain text: https://secwatch.observer/filing/0001213900-22-075030.txt

## Key facts
- Listing & Compliance Notices
  REVELATION BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: While the Company did complete a $5 million offering in July 2022, in the Form 10-Q for the quarter ended September 30,2022 the Company reported a stockholders’ equity of $2,227,768, less than the Stockholders’ Equity Requirement. As a result, on November 23, 2022, the Company received a further deficiency letter (the “Second Nasdaq Letter”). The Second Nasdaq
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/0001213900-22-075030-index.htm
- Listing & Compliance Notices
  REVELATION BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: Equity Requirement was based on the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, reporting the stockholders’ deficit of $98,511. Pursuant to the First Nasdaq Letter, the Company submitted a plan to regain compliance and the Company which contemplated capital raises of $10 million, following which Nasdaq
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/0001213900-22-075030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.